Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel Free EVFM Stock Alerts

Evofem Biosciences (EVFM) Competitors

Evofem Biosciences logo
$0.0075 +0.00 (+7.14%)
As of 01:06 PM Eastern
Compare

EVFM vs. GRI, ADXN, SXTP, CVKD, and XRTX

Should you buy Evofem Biosciences stock or one of its competitors? Evofem Biosciences's main competitors and comparable companies include GRI Bio (GRI), Addex Therapeutics (ADXN), 60 Degrees Pharmaceuticals (SXTP), Cadrenal Therapeutics (CVKD), and XORTX Therapeutics (XRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Evofem Biosciences compare to GRI Bio?

Evofem Biosciences (NASDAQ:EVFM) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Evofem Biosciences has higher revenue and earnings than GRI Bio. Evofem Biosciences is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.08$52.98M-$0.13N/A
GRI BioN/AN/A-$11.96M-$38.37N/A

In the previous week, GRI Bio had 2 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for GRI Bio and 0 mentions for Evofem Biosciences. GRI Bio's average media sentiment score of 0.93 beat Evofem Biosciences' score of 0.00 indicating that GRI Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Evofem Biosciences Neutral
GRI Bio Positive

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 0.6% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GRI Bio has a consensus price target of $21.00, indicating a potential upside of 1,254.84%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Evofem Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Evofem Biosciences has a beta of -1.37, meaning that its share price is 237% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.21, meaning that its share price is 221% less volatile than the broader market.

GRI Bio has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
GRI Bio N/A -134.03%-106.83%

Summary

GRI Bio beats Evofem Biosciences on 9 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to Addex Therapeutics?

Evofem Biosciences (NASDAQ:EVFM) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Evofem Biosciences has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.08$52.98M-$0.13N/A
Addex Therapeutics$210K18.07-$8.12M-$5.94N/A

Addex Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
Addex Therapeutics N/A -174.44%-126.47%

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Addex Therapeutics had 5 more articles in the media than Evofem Biosciences. MarketBeat recorded 5 mentions for Addex Therapeutics and 0 mentions for Evofem Biosciences. Addex Therapeutics' average media sentiment score of 0.49 beat Evofem Biosciences' score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Evofem Biosciences Neutral
Addex Therapeutics Neutral

Evofem Biosciences has a beta of -1.37, indicating that its stock price is 237% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Summary

Addex Therapeutics beats Evofem Biosciences on 8 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, 60 Degrees Pharmaceuticals had 5 more articles in the media than Evofem Biosciences. MarketBeat recorded 5 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Evofem Biosciences. 60 Degrees Pharmaceuticals' average media sentiment score of 0.48 beat Evofem Biosciences' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Neutral
Evofem Biosciences Neutral

Evofem Biosciences has higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M2.25-$7.36M-$4.82N/A
Evofem Biosciences$11.39M0.08$52.98M-$0.13N/A

60 Degrees Pharmaceuticals has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.37, meaning that its stock price is 237% less volatile than the broader market.

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evofem Biosciences has a net margin of -46.42% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-650.21% N/A -136.81%
Evofem Biosciences -46.42%-91.97%-61.93%

60 Degrees Pharmaceuticals presently has a consensus price target of $13.85, suggesting a potential upside of 1,438.89%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Evofem Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

60 Degrees Pharmaceuticals beats Evofem Biosciences on 10 of the 16 factors compared between the two stocks.

How does Evofem Biosciences compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Cadrenal Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.37, suggesting that its stock price is 237% less volatile than the broader market.

Evofem Biosciences has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadrenal TherapeuticsN/AN/A-$13.24M-$4.90N/A
Evofem Biosciences$11.39M0.08$52.98M-$0.13N/A

Cadrenal Therapeutics currently has a consensus target price of $13.00, suggesting a potential upside of 1,203.91%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Evofem Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cadrenal Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cadrenal Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cadrenal TherapeuticsN/A -406.41% -273.80%
Evofem Biosciences -46.42%-91.97%-61.93%

In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Evofem Biosciences. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for Evofem Biosciences. Cadrenal Therapeutics' average media sentiment score of 0.55 beat Evofem Biosciences' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cadrenal Therapeutics Positive
Evofem Biosciences Neutral

Summary

Cadrenal Therapeutics beats Evofem Biosciences on 9 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to XORTX Therapeutics?

Evofem Biosciences (NASDAQ:EVFM) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Evofem Biosciences has a beta of -1.37, indicating that its share price is 237% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Evofem Biosciences has higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.08$52.98M-$0.13N/A
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

XORTX Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
XORTX Therapeutics N/A -137.85%-108.16%

In the previous week, XORTX Therapeutics had 4 more articles in the media than Evofem Biosciences. MarketBeat recorded 4 mentions for XORTX Therapeutics and 0 mentions for Evofem Biosciences. XORTX Therapeutics' average media sentiment score of 1.02 beat Evofem Biosciences' score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Evofem Biosciences Neutral
XORTX Therapeutics Positive

Summary

XORTX Therapeutics beats Evofem Biosciences on 7 of the 12 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVFM vs. The Competition

Export
MetricEvofem BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$994K$12.42B$7.27B$12.97B
Dividend YieldN/A2.63%2.51%22.89%
P/E Ratio-0.01807.81275.4025.37
Price / Sales0.09748.45562.2978.82
Price / CashN/A86.6577.1653.04
Price / Book0.009.2110.555.95
Net Income$52.98M$2.84B$3.50B$380.75M
7 Day PerformanceN/A-4.00%-3.92%-3.96%
1 Month PerformanceN/A-8.07%-8.30%-6.81%
1 Year PerformanceN/A-5.86%2.35%-4.58%

Evofem Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVFM
Evofem Biosciences
N/A$0.01
+7.1%		N/A-47.0%$994K$11.39MN/A29
GRI
GRI Bio
3.4229 of 5 stars		$1.85
-2.6%		$21.00
+1,035.1%		-97.0%$4.15MN/AN/A5
ADXN
Addex Therapeutics
0.4997 of 5 stars		$3.14
-1.4%		N/A-63.8%$3.92M$210KN/A3
SXTP
60 Degrees Pharmaceuticals
2.6959 of 5 stars		$1.10
-0.9%		$13.85
+1,159.1%		-86.0%$3.90M$1.41MN/A3
CVKD
Cadrenal Therapeutics
2.8759 of 5 stars		$0.97
-1.8%		$13.00
+1,237.0%		-92.9%$3.53MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVFM) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
My next big call (under $1)
The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...
Crypto 101 Media | Sponsoredtc pixel
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...
Paradigm Press | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel